ID   A2780-E(80)
AC   CVCL_S476
SY   A2780 E(80)
DR   cancercelllines; CVCL_S476
DR   Wikidata; Q54606577
RX   PubMed=10772682;
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_H619 ! A2780-1A9
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 05-10-23; Version: 14
//
RX   PubMed=10772682; DOI=10.1093/jnci/92.8.642;
RA   Vandier D., Calvez V., Massaad-Massade L., Gouyette A., Mickley L.A.,
RA   Fojo T., Rixe O.;
RT   "Transactivation of the metallothionein promoter in cisplatin-resistant
RT   cancer cells: a specific gene therapy strategy.";
RL   J. Natl. Cancer Inst. 92:642-647(2000).
//